Vascular calcification and QT interval in incident hemodialysis patients.
This study proposes [corrected] to evaluate the impact of different phosphate binders on the slowing of [corrected]cardiovascular calcification [corrected] and QT dispersion in incident haemodialysis patients with a follow-up of [corrected] 36 months. This is to be a [corrected] randomized, multicenter, perspective, [corrected] interventional study. Inclusion criteria are age over 18 years and being an [corrected] incident patient [corrected] on hemodialysis. Exclusion criteria are congenital prolongation of QT segment syndrome, QT-c >440 ms, bradycardia <50 beats per minute, symptomatic [corrected] arrhythmia or any other significant heart problems; electrolyte imbalances [corrected] (especially hypokalemia, hypomagnesemia or [corrected] hypocalcemia); abnormal liver function tests and [corrected] hypothyroidism. An informed consent will be taken at study entry. The patients will be randomized to 2 cohorts: [corrected] 180 patients in the sevelamer [corrected] group and 180 patients in calcium-binder phosphate group. Related vascular calcification mortality is the principal end point [corrected] and will be evaluated at 36 months.
Di Iorio
Biagio Raffaele
BR
Nephrology and Dialysis Unit, Hospital Solofra, Avellino, Italy. br.diiorio@libero.it
Cucciniello
Emanuele
E
Bellizzi
Vincenzo
V
D001145:Arrhythmias, Cardiac / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D002114:Calcinosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002118:Calcium / Q000097:blood*; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002614:Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D010710:Phosphates / Q000097:blood*; D011073:Polyamines / Q000627:therapeutic use; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects*; D012107:Research Design; D000069603:Sevelamer; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D002614:Chelating Agents; D010710:Phosphates; D011073:Polyamines; D000069603:Sevelamer; D002118:Calcium